Avanir Settles With Wockhart Over Planned Nuedexta Generic

Law360, New York (September 6, 2013, 6:01 PM EDT) -- Avanir Pharmaceuticals Inc. said Friday it has reached a settlement with Wockhardt Ltd. over its planned generic version of mental health drug Nuedexta, ending a patent infringement dispute in Delaware federal court.

As part of the settlement, Aliso Viejo, Calif.-based Avanir said it has signed a licensing agreement with Wockhardt, allowing it to launch authorized generic dextromethorphan hydrobromide and quinidine sulfate capsules on July 30, 2026 — just before the Aug. 13, 2026, expiration of the last patent-in-suit. Wockhardt might be able to market the generic...
To view the full article, register now.